Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction

British Journal of Clinical Pharmacology

Volumn 61, Issue 2, 2006, Pages 200-210

  Yeo, Kwee Poo ^a   Lowe, Stephen L ^a   Lim, Ming Tung ^a   Voelker, James R ^b   Burkey, Jennifer L ^b   Wise, Stephen D ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

6 hydroxycortisol; CYP3A4; Enzyme induction; Protein kinase C ; Rifampicin; Ruboxistaurin

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450 3A4; DRUG METABOLITE; N DESMETHYLRUBOXISTAURIN; PROTEIN KINASE C INHIBITOR; RIFAMPICIN; RUBOXISTAURIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INDUCTION; HUMAN; MALE; MEDICAL ASSESSMENT; NORMAL HUMAN; PRIORITY JOURNAL; SAMPLE SIZE; SINGLE DRUG DOSE; URINALYSIS;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; HYDROCORTISONE; INDOLES; MALE; MALEIMIDES; PROTEIN KINASE C; RIFAMPIN;

EID: 33644898830     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02540.x     Document Type: Article

References (36)

1. Jirousek MR Gillig JR Gonzalez CM Heath WF McDonald JH rd. Neel DA Rito CJ Singh U Stramm LE Melikian-Badalian A Baevsky M Ballas LM Hall SE Winneroski LL Faul MM. (S)-13-[(Dimethylamino) methyl]-10,11,14,15-tetrahydro-4,9 : 16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1 bv,3 (2H)-dione (ruboxistaurin) and related analogues: Isozyme selective inhibitors of protein kinase C β J Med Chem 1996 39: 2664 71
2. Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema Surv Opthalmol 2002 47 Suppl 2 S263 9
3. Tuttle KR Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition Am J Kidney Dis 2003 42 456 65
4. Engel GL Farid NA Faul MM Richardson LA Winneroski LL. Salt form selection and characterization of ruboxistaurin mesylate monohydrate Int J Pharm 2000 198 239 47
5. Tesfamariam B Brown ML Deykin D. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta J Clin Invest 1990 85 929 32
6. Inoguchi T Battan R Handler E Sportsman JR Heath W King GL. Preferential elevation of protein kinase C isoform and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation Proc Natl Acad Sci USA 1992 89 11059 63
7. Ishii H. Jirousek MR, Koya D Takagi C Xia P Clermont A Bursell SE Kern TS Ballas LM Heath WF Stramm LE Feener EP King GL Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor Science 1996 272 728 31
8. Aiello LP Bursell SE Clermont A Duh E. Ishii H Takagi C Mori F Ciulla TA Ways K Jirousek M Smith LEH King GL Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor Diabetes 1997 46 1473 80
9. Ring BJ Gillespie JS Binkley SN Campanale KM Wrighton SA. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450 Drug Metab Dispos 2002 30 957 61
10. Studies on file. Clinical Investigator's Brochure for Ruboxistaurin Mesylate September 2004; Eli Lilly & Company, Indianapolis, IN, USA
11. Bachmann KA Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo Xenobiotica 1993 23 307 15
12. Slaughter RL Edwards DJ. Recent advances: the cytochrome P450 enzymes Ann Pharmacother 1995 29 619 24
13. Niemi M Backman JT Fromm MF Neuvonen PJ Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance Clin Pharmacokinet 2003 42 819 50
14. Galteau MM Shamsa F. Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals Eur J Clin Pharmacol 2003 59 713 33
15. Ged C Rouillon JM Pichard L Combalbert J Bressot N Bories P. MichelH, Beaune P, Maurel P. The increase in urinary excretion of 6-beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction Br J Clin Pharmacol 1989 28 373 87
16. Ohnhaus EE Breckenridge AM Park BK. Urinary excretion of 6-beta-hydroxycortisol and the time course measurement of enzyme induction in man Eur J Clin Pharmacol 1989 36 39 46
17. Lee C. Urinary 6[beta]-hydroxycortisol in humans. Analysis, biological variations and reference ranges Clin Biochem 1995 28 49 54
18. Tran JQ Kovacs SJ McIntosh TS Davis HM. Martin DE. Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction J Clin Pharmacol 1999 39 487 94
19. Johnston A Holt D Lee T Clark E Dunn K Boyce M. Urinary 6[beta]-hydroxycortisol. cortisol ratio as an in vivo marker of CYP3A4 activity - spot vs 24 h collections Br J Clin Pharmacol 2003 55 440
20. Zhiri A Wellman-Bednawska M Siest G. ELISA of 6-beta-hydroxycortisol in human urine: diurnal variations and effects of antiepileptic therapy Clin Chim Acta 1986 157 267 76
21. Kay L Kampmann JP Svendsen TL Vergman B Hansen JE Skovsted L Kristensen M. Influence of rifampicin and isoniazid on the kinetics of phenytoin Br J Clin Pharmacol 1985 20 323 6
22. Backman JT Kivisto KT Olkkola KT Neuvonen PJ. The area under the the concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin Eur J Clin Pharmacol 1998 54 53 8
23. Holtbecker N Fromm MF Kroemer HK Ohnhaus EE Heidemann H. The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism Drug Metab Dispos 1996 24 1121 34
24. Paine MF Shen DD Kunze KL Perkins JD Marsh CL McVicar JP Barr DM Gillies BS Thummel KE. First-pass metabolism by the human intestine Clin Pharmacol Ther 1996 60 14 24
25. Soon D Yeo KP Lim M Chan C Wise SD. CYP3A activity as determined by midazolam PK, is similar between Chinese, Indians and Caucasians before and after rifampicin treatment but not as determined by 6b-OH cortisol formation Clin Pharmacol Ther 2003 73 P20 PI 69
26. Schuetz EG Beck WT Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells Mol Pharmcol 1996 49 311 8
27. Westphal K Weinbrenner A Zschiesche M Franke G Knoke M Oertel R Fritz P von Richter O Warzok R Hachenberg T Kauffmann HM Schrenk D Terhaag B Kroemer HK Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction Clin Pharmacol Ther 2000 68 345 55
28. Kim RB Wandel C Leake B Cvetkovic M Fromm MF Dempsey PJ Roden MM Belas F Chaudhary AK Roden DM Wood AJ Wilkinson GR. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein Pharm Res 1999 16 408 14
29. Apseloff G Hilligoss DM Gardner MJ Henry EB Inskeep PB Gerber N Lazar JD. Induction of fluconazole metabolism by rifampin: in vivo study in humans J Clin Pharmacol 1991 31 358 61
30. Borin MT JH. Chambers Carel S Gagnon WW. Freimuth. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate Clin Pharmacol Ther 1997 61 544 53
31. Saima S Furuie K Yoshimoto H Fukuda J Hayashi T Echizen H. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects Br J Clin Pharmacol 2002 53 203 6
32. Uhr M Holsboer F Müller MB. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins J Neuroendocrinol 2002; 14 753 9
33. Watkins PB Turgeon DK Saenger P Lown KS Kolars JC Hamilton T Fishman K Guzelian PS Voorhees JJ. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity Clin Pharmacol Ther 1992 52 265 73
34. Lin Y Anderson GD Kantor E Ojemann LM Wilensky AJ. Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women J Clin Pharmacol 1999 39 578 82
35. Kinirons MT O'Shea D Downing TE Fitzwilliam AT Joellenbeck L Groopman JD Wilkinson GR Wood AJ. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men Clin Pharmacol Ther 1993 54 621 9
36. Kinirons MT O'Shea D Kim RB Groopman JD Thummel KE Wood AJ Wilkinson GR Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A Clin Pharmacol Ther 1999 66 224 31